Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10593 |
BPR1M97
|
Opioid Receptor | Endocrinology/Hormones; GPCR/G Protein; Neuroscience |
BPR1M97 是一种具有血脑屏障渗透性和有效性的 mu 阿片受体(MOP)和神经肽-啡肽 FQ(NOP)受体激动剂,对 MOP 的 Kis 值为1.8 nM,对 NOP 的Kis 值为 4.2 nM。BPR1M97 具有抗伤害作用和抗痛觉作用。 | |||
T2272 |
BPR1J-097
BPR1J097 |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
BPR1-J097 是新型的、强效的FLT3抑制剂 (IC50:11 nM)。 | |||
T4261 |
BPR1J-097 hydrochloride (1327167-19-0(free base))
|
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
BPR1J-097 hydrochloride (1327167-19-0(free base)) 是一种新型小分子 FLT-3抑制剂(IC50=11±7 nM),具有很好的体内抗肿瘤活性。 | |||
T40164 |
BPR1R024
BPR1R024 |
Others | Others |
BPR1R024 is an orally active and selective CSF1R inhibitor ( IC 50 = 0.53 nM). | |||
T71415 |
FPL-63012AR
|
Others | Others |
FPL-63012AR is a D1-receptor agonist. | |||
T71881 |
Bromophenol red
|
Others | Others |
Bromophenol red (BPR) is a chemical indicator. It has been shown to bind to lysozymes and inhibits their activity against bacterial cell walls, but not against the polysaccharide component of peptidoglycan. | |||
T70779 |
BPR1J-340
|
Others | Others |
BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibit... | |||
T10592 |
BPR1K871
DBPR114 |
FLT | Angiogenesis; Tyrosine Kinase/Adaptors |
BPR1K871 (DBPR114) 是一种高效选择性的 FLT3/AURKA 双重抑制剂,对 FLT3 和 AURKA 作用的 IC50值分别为 19 nM 和 22 nM。BPR1K871 具有抗癌治疗的潜力。 | |||
T71279 |
BPR1K653
|
Others | Others |
BPR1K653 is a potent Aurora kinase inhibitor with potential anticancder activity. BPR1K653 specifically inhibited the activity of Aurora-A and Aurora-B kinase at low nano-molar concentrations in vitro. BPR1K653 was potent in targeting a variety of cancer cell lines regardless of the tissue origin, p53 status, or expression of MDR1. At the cellular level, BPR1K653 induced endo-replication and subsequent apoptosis in both MDR1-negative and MDR1-positive cancer cells. Importantly, it showed potent ... | |||
T10965 |
DBPR112
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂,对 EGFRWT 和 EGFRL858R/T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。 | |||
T15079 |
DBPR108
|
Proteasome; DPP-4 | Proteases/Proteasome; Ubiquitination |
DBPR108是新型、具有口服活性、选择性的DPP4抑制剂,IC50=为15nM,对DPP8和DPP9基本无抑制。 | |||
T27125 |
DBPR-110
MB110,MB 110,MB-110 |
Others | Others |
DBPR-110 is a nonstructural protein 5A (NS5A) inhibitor. DBPR-110 reduced the reporter expression of the HCV1b replicon with a EC(50) and a selective index value of 3.9 ± 0.9 pM and >12,800,000, respectively. DBPR-110 reduced HCV2a replicon activity with | |||
T69498 |
DBPR112 HCl
|
Others | Others |
DBPR112 is a potent EGFR inhibitor (IC50=487 nM) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. DBPR112), DBPR112 not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib,against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib alon... | |||
T71278 |
IBPR002
|
Others | Others |
IBPR002 is an aurora kinase inhibitor which reveals mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules. | |||
T34994 |
Uk-390957
Uk390957,Uk 390957 |
Others | Others |
Uk-390957 是一种磺酰胺化合物,由于与碳酸酐酶结合而具有高BPR。 |